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ABSTRACT
The new era of cancer genomics is providing us with
extensive knowledge of mutations and other alter-
ations in cancer. The Cancer3D database at http:
//www.cancer3d.org gives an open and user-friendly
way to analyze cancer missense mutations in the
context of structures of proteins in which they are
found. The database also helps users analyze the
distribution patterns of the mutations as well as their
relationship to changes in drug activity through two
algorithms: e-Driver and e-Drug. These algorithms
use knowledge of modular structure of genes and
proteins to separately study each region. This ap-
proach allows users to find novel candidate driver
regions or drug biomarkers that cannot be found
when similar analyses are done on the whole-gene
level. The Cancer3D database provides access to the
results of such analyses based on data from The Can-
cer Genome Atlas (TCGA) and the Cancer Cell Line
Encyclopedia (CCLE). In addition, it displays muta-
tions from over 14 700 proteins mapped to more than
24 300 structures from PDB. This helps users visu-
alize the distribution of mutations and identify novel
three-dimensional patterns in their distribution.
INTRODUCTION
Some of the most practical issues to explore in cancer re-
search are the detection of cancer drivers and the identi-
fication of biomarkers that predict a patient’s response to
a drug (1–4). Recent publication of several large-scale can-
cer datasets, such as The Cancer Genome Atlas (TCGA)
(5) or the Cancer Cell Line Encyclopedia (CCLE) (6), pro-
vides means to explore such questions from a genome-wide
perspective in hundreds or thousands of samples. Various
tools and databases have been developed to provide ac-
cess and allow analysis of these data, such as UCSC’s Can-
cer Genomics Browser (7), canSAR (8), cBioPortal (9) or
COSMIC (10). Most of these databases, however, do not
integrate genomic data such as missense mutations with
protein-structure information. Even if they do, as in the
case of canSAR, or cBioPortal they invariably focus ei-
ther on whole-proteins or individual mutations. None of
the existing databases use information regarding the differ-
ent protein functional regions (PFRs) in a protein in their
analyses. Integrating PFRannotations is important because
gene-centric methods can confuse or dilute signals where
only mutations at some specific positions within a protein
are relevant (11–14), whereas analyses focusing on individ-
ual mutations usually lack statistical power. Last but not
least, many databases do not allow the exploration of can-
cer drivers and biomarkers at the same time.
Cancer3D integrates data from TCGA and CCLE and
allows users to explore the biomarker and driver problems
at the same time through two novel algorithms: e-Driver
(13) and e-Drug (15). These algorithms are unique in us-
ing information about the modular structure of a protein
to predict novel cancer drivers or drug biomarkers, respec-
tively. Statistics are calculated separately for each region in
each protein, including known PFAM domains (16), pre-
dicted intrinsically disordered regions and over 1300 po-
tential novel domains in the human proteome detected by
AIDA (17). Another important feature of Cancer3D is that
it maps somatic missense mutations from over 18 000 hu-
man proteins to, wherever available, experimental or pre-
dicted protein three-dimensional structures. The Cancer3D
database not only displays the mutated positions of a pro-
tein in their corresponding structures, but also conveys im-
portant information such as drug activity or mutation fre-
quency by color-coding. This helps users to quickly identify
three-dimensional patterns in data such as clustering of mu-
tation hotspots around particular regions (Figure 1).
MATERIALS AND METHODS
Data sources
Mutation data used in Cancer3D come from the CCLE and
TCGA pancancer analysis projects. In both cases, we used
theVariant Effect Predictor Tool tomapmutations from ge-
nomic coordinates to all ENSEMBL protein isoforms (18).
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Figure 1. Database sources, content and main view. The database allows users to simultaneously access two types of cancer data: mutation frequency
(from TCGA) and pharmacogenomic profiles (from CCLE). When a user queries the database with a protein name, Cancer3D retrieves these data and
analyzes them using e-Driver and e-Drug, respectively. The user can also view where the mutations are located in different structures from PDB and
navigate through the different protein regions and structures using the protein viewer. Finally, Cancer3D also provides information on which proteins are
interacting with the query according to Human Protein Reference Database (HPRD), allowing users to either go to references describing the interaction
or to query Cancer3D with those proteins.
We have a total of 275 648 mutations mapped onto 103 918
protein isoforms that belong to 23 226 unique genes.
Protein domainswere assigned using PfamHMMmodels
as retrieved from ENSEMBL through its application pro-
gramming interface (API), whereas intrinsically disordered
regions were predicted using Foldindex (19) (we used re-
gions with a score below – 0.1). The coordinates of novel
protein domains were identified by the AIDA server (17)
and curated manually. Overall results for 272 188 individ-
ual regions in the human proteome are currently stored in
Cancer3D: 156 147 Pfam domain annotations, 103 986 in-
trinsically disordered regions and 12 055 novel domains.
Note that these numbers include all annotations for all iso-
forms of a gene. For example, since Epidermal Growth Fac-
tor Receptor (EGFR) has three different isoforms with an
instance of PF00069 (protein kinase domain), each of them
will be counted separately. We have also included a list of
protein–protein interactions from HPRD (20) in order to
allow users to explore not only their favorite protein, but
also the protein’s interaction partners.
Drug activity data for the 24 anticancer drugs were
downloaded from the CCLE and calculated using eight-
point dose–response curves in 479 different cell lines. These
curves are adjusted to a logistical-sigmoidal function and
described by four different variables: (i) the maximal effect
level (Amax), (ii) the drug concentration at half-maximal ac-
tivity of the compound (EC50), (iii) the concentration at
which the drug response reached an absolute inhibition of
50% (IC50) (iv) and the activity area that is the area above
the dose–response curve. In order to simplify the analysis in
Cancer3D, we used values regarding the activity area only.
According to the CCLE, the activity area captures simulta-
neously both variables of drug activity: its efficacy and its
potency.
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Algorithms
We have previously developed two algorithms called e-
Driver (13) and e-Drug (15) that allow the identification of
candidate cancer driver genes and drug biomarkers, respec-
tively. The main novel feature of both algorithms is that in-
stead of analyzing data in terms of genes, they focus on re-
gions corresponding to Pfam domains or intrinsically dis-
ordered regions. Similar approaches have been previously
used in the context of mutations associated withMendelian
disorders (11,12). Users can find detailed explanations of
the algorithms on Cancer3D’s help page and in the individ-
ual manuscripts.
Structure mapping
We used BLAST (21) to match sequences of three-
dimensional structures to all our domains. The full PDB
(March 2014 including non-human proteins) was queried
for each protein sequence in Cancer3D. PDB structures
were assigned to each protein that had an e-value below 1e-
6. The BLAST output was used to map mutated positions
onto the structures.
USING THE DATABASE
In the following paragraphs, we will present a use-case sce-
nario with all input and views based on the BRAF pro-
tein. This is a well-known oncogene for which a drug tar-
geting the V600E mutation has been recently approved for
metastatic melanoma treatment in the USA and in Europe
in 2011 and 2012, respectively (22). The drug, which goes
under the commercial name of Vemurafenib, is part of the
CCLE under the synonym PLX4720.
Input and isoform selection
The start page contains one input field to search for the
user’s protein of interest. The user can input a gene or a pro-
tein name, a Uniprot ID, or an ENSEMBL Gene/Protein
ID. If the name is recognized by the database, a list of pro-
tein isoforms identified by their ENSEMBL protein ID will
be listed. Information displayed also includes the respec-
tive sequence length and the number of mutations in both
TCGA and CCLE. Isoforms are sorted by their individual
sequence lengths, and the longest isoform is highlighted for
quick selection. The user also has an option to select either
e-Driver or e-Drug results for the next page.
In our use-case scenario, the user would specify BRAF
in the input menu and select the first isoform (ENSEMBL
protein id: ENSP00000288602) and e-Driver. For the user
interested in just browsing and getting familiar with the
database, we provide a link to a ‘protein of the month’ that
leads to a preselected protein.
After the initial selections, the user is forwarded to the
main page (Figure 2). The main page can essentially have
two views: (i) the e-Driver or (ii) the e-Drug view. Switch-
ing between these views is possible by selecting a region or
region–drug combination in the respectivemenus. The ‘Mu-
tation Frequency’ or ‘Drug’ buttons in the menu bar allow
the user to immediately switch between the e-Driver and e-
Drug views for the currently selected region. The user can
access view-specific help texts for the current view state by
clicking on one of the question-mark symbols.
Main e-Driver view
After the user has chosen an isoform, themain analysis page
will be displayed for the combination of the selected iso-
form and view. For the e-Driver view, we display properties
of the region with the lowest P-value calculated by the e-
Driver algorithm. The upper left view initially contains the
‘Mutation Frequency’: a histogram plot depicting the muta-
tion frequency for each residue where the current domain is
highlighted in red (Figure 2). The upper right view displays
a placeholder image for the three-dimensional model of the
region (experimental or predicted). In order to view the in-
teractive three-dimensional structure, the user has to click
on the placeholder image. The structure displayed will have
each residue colored according to its mutation frequency.
Residues with higher mutation rates are colored in more-
intense red tones, while positions with lower mutation rates
are colored in less-intense red tones.
Viewing other regions is possible by selecting them either
from the region viewer, where they are listed according to
their occurrence in sequence, or from the e-Driver menu,
where they are sorted according to their P-value.
For our BRAF use-case scenario, the user would see the
‘Mutation Frequency’ displayed for the PF00069 domain
and chain B of the PDB structure 2HEN with the muta-
tion sites colored according to the mutation frequency. The
algorithm identifies BRAF’s kinase domain as a potential
cancer driver domain because it is highly enriched in mis-
sense mutations in the TCGA dataset (P < 1e−6), particu-
larly in the V600 position (shown in red in the structure).
Main e-Drug view
If the user enables the e-Drug option on the start page,
the main page will load into the e-Drug view. The graph
in the left view will display the ‘Drug Activity Area’ for
the region–drug combination with the lowest P-value. The
region-specific drug activity region is highlighted in red.
The structure on the right visualizes the spatial drug speci-
ficity for each residue, but must be enabled by clicking on
the placeholder image first. All other region–drug combi-
nations are listed in the e-Drug menu, sorted by their P-
values. Selection of either one of these combinations will
display the ‘PFR-Drug Scatterplot’ in the top left view and
the ‘Drug Boxplot’ for the selected region and drug. Here,
activity of the current drug is compared in three different
groups of cell lines: cell lines with mutations in the selected
region, cell lines with mutations in other regions of the pro-
tein and cell lines with no somaticmissensemutations in any
region of the current protein (shown asWT in the boxplot).
In order to investigate the region–drug combination
with the lowest P-value in our BRAF use-case sce-
nario, the user would select the PF07714 (tyrosine kinase)
domain––PLX4720 (Vemurafenib) drug combination in the
e-Drug menu. Selecting this combination would display the
respective ‘PFR-Drug Scatterplot’ and ‘Drug Boxplot’ in the
top views. Clicking the assigned PDB structure displays the
latter with all mutation sites colored according to the drug
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Figure 2. Different states of the main view. (A) Consistent with our use-case scenario of BRAF (ENSEMBL protein id: ENSP00000288602), the user
would see this initial view. The upper left box contains the ‘Mutation Frequency’ plot for the whole protein as detected by the e-Driver algorithm. The red
region in the plot highlights the region with the lowest P-value (PF00069). The three-dimensional structure in the right box is the best homolog for the
current domain. In this structure, mutated residues are highlighted according to the observed mutation frequency where white is the lowest and red is the
highest observedmutation frequency. The ‘RegionAnnotations’ box allows the user to select alternative regions: either PFAMdomains (yellow), intrinsically
disordered regions (blue) or newly annotated domains (red). The green boxes mark regions for which structures have been found. The interaction box lists
all interacting proteins for the currently selected one and allows the user to either view the paper in which this particular interaction was described or
investigate a particular interaction partner with Cancer3D. The first menu element, ‘Regions’, in the menu bar allows the user to select regions (similar
to ‘Region Annotations’). e-Driver allows users to select regions sorted by their P-values. The e-Drug menu element allows the user to browse through
region–drug combinations sorted according to their P-values detected by the e-Drug algorithm. (B) By clicking on one of the entries in the e-Drug menu,
the two upper boxes will display the ‘PFR-Drug Scatterplot’ and the ‘Drug boxplot’ for the particular region–drug combination. Notably, the structure
view disappears but can be reactivated by selecting the corresponding PDB domain in the ‘Region Annotations’ view. (C) Now, all mutated residues are
highlighted based on their drug activity, where red residues have low activity and blue residues have high activity.
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activity. Mutations found in cell lines with lower drug ac-
tivity are colored in red, whereas those found in cell lines
with higher drug activity are shown in blue. When a mu-
tation is found in multiple cell lines, the coloring reflects
the average activity in such cells. In the case of the BRAF
kinase––PLX4720 (Vemurafenib) pair from our use case
(Figure 2)––one can observe in the Drug Scatterplot that
the cell lines with mutations in BRAF that mostly respond
to this drug are those with mutations in the V600 position.
The mutation can also be quickly identified in the structure,
as the V600 position appears clearly shown in blue.
Region viewer
We use a custom region viewer plugin to visualize the po-
sition of PFAM domains, intrinsically disordered regions
and new hypothetical domains in the protein. These three
types are displayed in yellow, blue and red boxes, respec-
tively. Green boxes indicate regions matching or homolo-
gous to available protein structures. The user can click and
select any region of interest, leading to the specific analysis
(either for e-Driver or for e-Drug, depending on the current
view) for that particular region.
Interaction viewer
In the bottom right area, we list all interaction partners for
the protein under scrutiny. For each interaction, we pro-
vide the user with a link to the respective publication where
the interaction between both proteins has been described. A
link to all isoforms in the database for the interacting part-
ner allows the user to continue investigating e-Driver and
e-Drug results for their respective interaction partners. Fi-
nally, the ‘Show structure’ button allows the user to view
a three-dimensional model of the interaction in the upper
right window. The button is activated and highlighted in
blue whenever a matching complex for the interacting pro-
teins was found. Gray ‘Show Structure’ buttons indicate
that no structures for the particular interaction were found.
Tissue selection
Cancer3D returns, by default, the results obtained using all
the available data. While it increases the statistical power of
the analysis, it hides tissue-specific results. For example, we
have previously shown that the mutation patterns in EGFR
are drastically different in the glioblastoma and lung ade-
nocarcinoma datasets from TCGA (13). The user can focus
on a specific cancer type by clicking on the ‘Tissue’ button
and selecting the desired option.
Precomputed results
The ‘Precomputed’menu provides direct links to results dis-
cussed in our previous publications where we first intro-
duced the algorithms. These links aim at helping the user
to find biologically relevant results identified by our algo-
rithms.
Other pages
In order to help making the most of Cancer3D, we provide
a series of pages with tutorials and a guideline explaining
issues regarding P-values, multiple testing corrections and
specific details of the algorithms and datasets that are part
of Cancer3D. The user finds this page in the ‘Support’ menu
by selecting then the ‘P-Value explained’ entry.
CONCLUSIONS AND FUTURE DEVELOPMENTS
We developed Cancer3D to present and distribute results
of our novel algorithms e-Driver and e-Drug in a user-
friendly manner. These algorithms exploit the knowledge
of the inner structure of proteins to detect novel drivers
and drug biomarkers, respectively. The database also pro-
vides a means to explore somatic missense mutations from
TCGA and CCLE mapped onto over 24 300 structures, as
well as 1300 potential novel protein domains identified by
the AIDA server.
Our ongoing research in this field will expand the con-
tent of this database, and we will continuously extend the
server with results stemming from our future algorithms.
In the short term, we plan to integrate other tools devel-
oped by our group into the database to expand the result
spectrum on the web pages. For example, we are working
on an interface to AIDA to allow users to generate mod-
els of their proteins directly from Cancer3D. This feature
would enable three-dimensional visualization of mutations
for structurally unknown domains. We will provide an API
to allow developers to access our database programmati-
cally. In order to extend our structural mappings, we plan
to include mappings from FFAS (23).
Finally, we intend to expand the database by including
other types of mutations relevant to cancer, such as copy-
number variations (24) or synonymous mutations (25), as
well as data from other cancer genomics projects, such as
the International Cancer Genome Consortium (26) or the
Genomics of Drug Sensitivity in Cancer (27).
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